Tags

Type your tag names separated by a space and hit enter

Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV.
Front Cell Infect Microbiol. 2023; 13:1180344.FC

Abstract

Nipah virus (NiV) and Hendra virus (HeV) are newly emerging dangerous zoonotic pathogens of the Henipavirus genus of the Paramyxoviridae family. NiV and HeV (HNVs) which are transmitted by bats cause acute respiratory disease and fatal encephalitis in humans. To date, as there is a lack of antiviral drugs or effective antiviral therapies, the development of vaccines against those two viruses is of primary importance, and the immunogen design is crucial to the success of vaccines. In this study, the full-length protein (G), the ectodomain (Ge) and the head domain (Gs) of NiV attachment glycoprotein were delivered by the replication-defective type 5 adenovirus vector (Ad5) respectively, and the recombinant Ad5-NiV vaccine candidates (Ad5-NiVG, Ad5-NiVGe and Ad5-NiVGs) were constructed and their immunogenicity were evaluated in mice. The results showed that all the vaccine candidates stimulated specific humoral and cellular immune responses efficiently and rapidly against both NiV and HeV, and the Ad5-NiVGe elicited the strongest immune responses after a single-dose immunization. Furthermore, the potent conserved T-cell epitope DTLYFPAVGFL shared by NiV and HeV was identified in the study, which may provide valid information on the mechanism of HNVs-specific cellular immunity. In summary, this study demonstrates that the Ad5-NiVGe could be a potent vaccine candidate against HNVs by inducing robust humoral and cellular immune responses.

Links

Authors+Show Affiliations

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China. College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China. College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.

MeSH

HumansAnimalsMiceHendra VirusNipah VirusVirus AttachmentGlycoproteinsVaccines, SyntheticImmunity, CellularAdenoviridae

Pub Type(s)

Journal Article

Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

37577376

Citation

Huang, Xiaoyan, et al. "Nipah Virus Attachment Glycoprotein Ectodomain Delivered By Type 5 Adenovirus Vector Elicits Broad Immune Response Against NiV and HeV." Frontiers in Cellular and Infection Microbiology, vol. 13, 2023, p. 1180344.

Huang X, Li Y, Li R, et al. Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV. Front Cell Infect Microbiol. 2023;13:1180344.

Huang, X., Li, Y., Li, R., Wang, S., Yang, L., Wang, S., Yin, Y., Zai, X., Zhang, J., & Xu, J. (2023). Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV. Frontiers in Cellular and Infection Microbiology, 13, 1180344. https://doi.org/10.3389/fcimb.2023.1180344

Huang X, et al. Nipah Virus Attachment Glycoprotein Ectodomain Delivered By Type 5 Adenovirus Vector Elicits Broad Immune Response Against NiV and HeV. Front Cell Infect Microbiol. 2023;13:1180344. PubMed PMID: 37577376.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV. AU - Huang,Xiaoyan, AU - Li,Yaohui, AU - Li,Ruihua, AU - Wang,Shaoyan, AU - Yang,Lu, AU - Wang,Shuyi, AU - Yin,Ying, AU - Zai,Xiaodong, AU - Zhang,Jun, AU - Xu,Junjie, Y1 - 2023/07/27/ PY - 2023/03/06/received PY - 2023/07/04/accepted PY - 2023/8/15/medline PY - 2023/8/14/pubmed PY - 2023/8/14/entrez KW - Hendra virus KW - Nipah virus KW - T-cell epitope KW - adenovirus vector KW - attachment glycoprotein KW - vaccine SP - 1180344 EP - 1180344 JF - Frontiers in cellular and infection microbiology JO - Front Cell Infect Microbiol VL - 13 N2 - Nipah virus (NiV) and Hendra virus (HeV) are newly emerging dangerous zoonotic pathogens of the Henipavirus genus of the Paramyxoviridae family. NiV and HeV (HNVs) which are transmitted by bats cause acute respiratory disease and fatal encephalitis in humans. To date, as there is a lack of antiviral drugs or effective antiviral therapies, the development of vaccines against those two viruses is of primary importance, and the immunogen design is crucial to the success of vaccines. In this study, the full-length protein (G), the ectodomain (Ge) and the head domain (Gs) of NiV attachment glycoprotein were delivered by the replication-defective type 5 adenovirus vector (Ad5) respectively, and the recombinant Ad5-NiV vaccine candidates (Ad5-NiVG, Ad5-NiVGe and Ad5-NiVGs) were constructed and their immunogenicity were evaluated in mice. The results showed that all the vaccine candidates stimulated specific humoral and cellular immune responses efficiently and rapidly against both NiV and HeV, and the Ad5-NiVGe elicited the strongest immune responses after a single-dose immunization. Furthermore, the potent conserved T-cell epitope DTLYFPAVGFL shared by NiV and HeV was identified in the study, which may provide valid information on the mechanism of HNVs-specific cellular immunity. In summary, this study demonstrates that the Ad5-NiVGe could be a potent vaccine candidate against HNVs by inducing robust humoral and cellular immune responses. SN - 2235-2988 UR - https://www.unboundmedicine.com/medline/citation/37577376/Nipah_virus_attachment_glycoprotein_ectodomain_delivered_by_type_5_adenovirus_vector_elicits_broad_immune_response_against_NiV_and_HeV_ DB - PRIME DP - Unbound Medicine ER -